Additional file 3: of Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer

Figure S1. Comparison of somatic mutation frequency between IBC and non-IBC in four subgroups. (a) The percentage of samples with somatic mutation in the TNBC subgroup; (b) the percentage of samples with somatic mutation in the HR–/HER2+ subgroup; (c) the percentage of samples with somatic mutation in the HR+/HER2– subgroup; (d) the percentage of samples with somatic mutation in the HR+/HER2+ subgroup. The gray bars indicate non-IBC, the black bars indicate IBC; *p < 0.05, **p < 0.01, ***p < 0.001. (PDF 52 kb

Additional file 5: of Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer

Figure S3. DNA copy number alterations in the IBC cohort. The genes with DNA copy number alterations are grouped along the x axis, the percentage of samples with DNA copy number alterations shown on the y axis, DNA amplifications are indicated by black bars above the x axis, and DNA deletions are indicated by gray bars below the x axis. (PDF 164 kb

Additional file 6: of Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer

Figure S4. MFS curves stratified by PIK3CA mutation in three subgroups of IBC patients. (a) Kaplan-Meier estimates of MFS according to PIK3CA mutations in patients of the HR– subgroup, (b) Kaplan-Meier estimates of MFS according to PIK3CA mutations in patients of the HER2+ subgroup, (c) Kaplan-Meier estimates of MFS according to PIK3CA mutations in patients of the HR+ subgroup. (PDF 42 kb

Additional file 4: of Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer

Figure S2. Comparison of biological pathway between IBC and non-IBC in four subgroups. (a) The percentage of samples with alteration on 10 biological pathways in the TNBC subgroup; (b) the percentage of samples with alteration on 10 biological pathways in the HR–/HER2+ subgroup; (c) the percentage of samples with alteration on 10 biological pathways in the HR+/HER2– subgroup; (d) the percentage of samples with alteration on 10 biological pathways in the HR+/HER2+ subgroup. The gray bars indicate non-IBC, the black bars indicate IBC; *p < 0.05, **p < 0.01, ***p < 0.001. (PDF 41 kb

Additional file 2: of Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer

Table S2. BreastCurie gene panel for targeted NGS. (PDF 411 kb

Additional file 1: of Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer

Table S1. Pathological and clinical characteristics of non-IBC cohorts. (PDF 169 kb